What is ANI Pharmaceuticals's D&A?

ANI Pharmaceuticals (ANIP) reported D&A of $20.92M in Q1 2026.

How has ANI Pharmaceuticals's D&A changed year-over-year?

ANI Pharmaceuticals's D&A decreased by 8.6% year-over-year, from $22.89M to $20.92M.

What is the long-term trend for ANI Pharmaceuticals's D&A?

Over 4 years (2021 to 2025), ANI Pharmaceuticals's D&A has grown at a 17.9% compound annual growth rate (CAGR), from $47.25M to $91.42M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

ANI Pharmaceuticals ANIP D&A

D&A at other companies

ViatrisVTRS

$676.1M+1.7%

AnaptysBio, Inc.ANAB

$130K-11.0%

ALN

Alnylam PharmaceuticalsALNY

$13.55M-5.9%

Aurinia PharmaceuticalsAUPH

$4.82M-0.8%

AmgenAMGN

$1.12B-19.5%

Viridian Therapeutics, Inc.VRDN

$121K+3.4%

Segments

By segment

See full

Generics and Other$0—

Rare Disease and Brands$0—

Other financials

Income statement

See full

Revenue$237.5M+20.5%

Gross profit$143.9M+16.0%

Operating income$38.9M+48.5%

Net income$29.5M+88.1%

EPS (diluted)$1.28+85.5%

Balance sheet

See full

Cash & equivalents$311.2M+108%

Total debt$305.3M-3.5%

Total equity$562.3M+34.3%

Total assets$1.4B+10.0%

Cash flow

See full

Operating cash flow$58.4M+66.8%

CapEx$6.1M+146%

Free cash flow$52.3M+60.8%

Valuation

See full

Market cap$1.89B+18.3%

Enterprise value$1.88B+5.8%

P/E20.5×—

P/S2×-0.3×

Profitability

See full

Gross margin60.8%+1.5pp

Operating margin13.4%—

Net margin10%+8.1pp

FCF margin20.7%+10.8pp

Returns & leverage

See full

Return on equity18.8%+15.6pp

Debt / equity0.5×-0.2×

Current ratio3.1×+0.5×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OtherDepreciationAndAmortization.

The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about ANI Pharmaceuticals's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ANI Pharmaceuticals's D&A?: ANI Pharmaceuticals (ANIP) reported D&A of $20.92M in Q1 2026.
How has ANI Pharmaceuticals's D&A changed year-over-year?: ANI Pharmaceuticals's D&A decreased by 8.6% year-over-year, from $22.89M to $20.92M.
What is the long-term trend for ANI Pharmaceuticals's D&A?: Over 4 years (2021 to 2025), ANI Pharmaceuticals's D&A has grown at a 17.9% compound annual growth rate (CAGR), from $47.25M to $91.42M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.